Skip to content

Awe Inducing Elements in Virtual Reality Applications: A Prospective Study of Hospitalized Children

Awe Inducing Elements in Virtual Reality Applications: A Prospective Study of Hospitalized Children

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05743062
Enrollment
202
Registered
2023-02-24
Start date
2023-06-29
Completion date
2023-08-03
Last updated
2024-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Awe

Keywords

Virtual Reality

Brief summary

This is an experimental study to evaluate which aspects of virtual reality (VR) software development can be optimized to increase awe in pediatric perioperative patients and their adult caregivers (e.g., parents, guardians)

Detailed description

Hospitalized pediatric patients, especially those undergoing anesthesia and surgery, experience anxiety and fear, resulting in lack of cooperation, withdrawal, and aggression. These reactions delay medical care and negatively impact patient experience. This is an experimental, prospective study to evaluate which aspects of virtual reality (VR) software development can be optimized to increase awe in pediatric perioperative patients and their adult caregivers. The primary center for this study will be Lucile Packard Children's Hospital Stanford (LPCHS) (located within Stanford University, Palo Alto, CA). After software development, we will evaluate the awe and engagement of pediatric patients after experiencing the novel virtual reality application.

Interventions

BEHAVIORALVirtual Reality

Virtual reality intervention will be given 6 times in total and each session will last not more than 60 seconds. Participants will be asked to fill out a survey before the intervention to collect the baseline data, after each session of VR intervention and a final survey at the end of the study.

OTHERControl

For case control, participants will service as their self control and no VR intervention will be given at first. Participants will be asked to fill out a survey before the intervention to collect the baseline data.

Sponsors

Stanford University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
6 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Patient with age range from 6 to 25 * Adult or LAR with age range from 18 to 99 * Able to consent or have parental consent * in pre-operative holding and inpatient acute care areas of LCPH * English speaking participants

Exclusion criteria

* People who do not consent * Significant Cognitive Impairment * History of Severe Motion Sickness * Visual Problems * currently have nausea * history of seizures * non-english participants

Design outcomes

Primary

MeasureTime frameDescription
Change in awe levels measured by Global Perceived Awe SurveyDuration of intervention, approximately 20-30 minutesGlobal Perceived Awe Survey contains an 7-point Likert scale . Scores range from 1 (strongly disagree) to 7 (Strongly agree), with higher score indicates strongly agree to the statement.

Secondary

MeasureTime frameDescription
Change in engagement measured by Game Engagement QuestionnaireDuration of intervention, approximately 20-30 minutesGame Engagement Questionnaire contains 19 items . Scores range from 1 (strongly disagree) to 7 (Strongly agree), with higher score indicates strongly agree to the statement.
Change in awe levels measured by Perceived Vastness SurveyDuration of intervention, approximately 20-30 minutesPerceived Vastness Survey contains 4 items . Scores range from 1 (strongly disagree) to 7 (Strongly agree), with higher score indicates strongly agree to the statement.
Change in awe levels measured by Perceived Need for Accommodation SurveyDuration of intervention, approximately 20-30 minutesPerceived Need for Accommodation Survey contains 3 items . Scores range from 1 (strongly disagree) to 7 (Strongly agree), with higher score indicates strongly agree to the statement.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026